Zai Lab Ltd. announced that the Phase 1b/3 FORTITUDE-102 clinical trial evaluating bemarituzumab in combination with chemotherapy and nivolumab for first-line gastric cancer has been stopped due to inadequate efficacy. The decision to halt the study followed an ad hoc analysis requested by the data monitoring committee, as disclosed by Amgen, the study sponsor, during its Q3 2025 earnings call. The company indicated it will continue to collaborate with Amgen and provide further updates as appropriate. Results from the trial have already been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.